71 results
8-K
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
of healthcare benefits for a period of 12 months following such termination (formerly, nine months under the 2017 Executive Severance Policy). Our … executive officers resident in the U.K. may elect to waive continuation of payment of healthcare premiums and accept a payment in lieu of such premiums
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
and that such provision of healthcare does not result in discrimination in the Company’s healthcare plan in which Executive participates under Section … and that such provision of healthcare does not result in discrimination in the Company’s healthcare plan in which Executive participates under Section 105(h) of the Code
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
15 May 24
Adaptimmune Reports Q1 2024 Financial and Business Updates
7:39am
aimed at educating healthcare providers about TCR T-cell therapy in solid tumors, including synovial sarcoma, and the role of biomarkers and testing
8-K
EX-10.1
xo5nml15
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
tyhld663vvq6
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
8-K
EX-99.1
znqug4 nb
4 Jan 24
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million – Presentation at JP Morgan Healthcare Conference
7:46am
424B3
y36n8
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
bgh1vhr i2d16qffrnwv
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
b57koslyc 8ga5epw
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.01
2lqjqxe62ldns8e0ndvx
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-99.1
ivr9qcstuilr8bf3hb
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am